cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Anaptysbio Inc
7 own
5 watching
Current Price
$14.9
$0.28
(1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,024.41M
52-Week High
52-Week High
41.30800
52-Week Low
52-Week Low
12.51000
Average Volume
Average Volume
1.32M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
121.2182
iconMarket Capitalization1,024.41M
icon52-Week High41.30800
icon52-Week Low12.51000
iconAverage Volume1.32M
iconDividend Yield--
iconP/E Ratio121.2182
What does the Anaptysbio Inc do?
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.
Read More
How much money does Anaptysbio Inc make?
News & Events about Anaptysbio Inc.
Globe Newswire
1 year ago
Rapid and sustained efficacy demonstrated in GPP patients after only a single dose, achieving primary endpoint at Week 4Flare control sustained on monthly subcutaneous doses through Week 16Imsidolimab was generally safe and well tolerated with low overall ADA incidenceTop-line GEMINI-1 Phase 3 trial...
Ticker Report
1 year ago
AnaptysBio, Inc. (NASDAQ:ANAB Get Rating) Wedbush issued their Q1 2024 earnings estimates for shares of AnaptysBio in a report released on Thursday, March 2nd. Wedbush analyst D. Nierengarten expects that the biotechnology company will earn ($1.11) per share for the quarter. The ...
Globe Newswire
2years ago
SAN DIEGO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up ...
Globe Newswire
2years ago
Pivotal Phase 3 (Part 1) trial demonstrates JEMPERLI plus chemotherapy significantly improved PFS versus chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer First-in-class pivotal data in endometrial cancer, if approved, to be a potential significant driver of...
Globe Newswire
2years ago
Positive headline results from PERLA, a head-to head Phase 2 trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancerCOSTAR, a Phase 2 trial of JEMPERLI plus cobolimab, an anti-TIM-3 antagonist antibody licensed to TESARO, Inc. (GSK) as part of the same ...
Frequently Asked Questions
Frequently Asked Questions
What is Anaptysbio Inc share price today?
plus_minus_icon
Can Indians buy Anaptysbio Inc shares?
plus_minus_icon
How can I buy Anaptysbio Inc shares from India?
plus_minus_icon
Can Fractional shares of Anaptysbio Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Anaptysbio Inc stocks?
plus_minus_icon
What is today’s traded volume of Anaptysbio Inc?
plus_minus_icon
What is today’s market capitalisation of Anaptysbio Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Anaptysbio Inc?
plus_minus_icon
What percentage is Anaptysbio Inc down from its 52-Week High?
plus_minus_icon
What percentage is Anaptysbio Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$14.9
$0.28
(1.92%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$41.54
$-1.06 (-2.49 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$65.84
$1.82 (2.84 %)
CABALETTA BIO INC
CABALETTA BIO INC
$2.19
$0.03 (1.62 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$0.64
$-0.05 (-7.40 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$41.54
$-1.06 (-2.49 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$65.84
$1.82 (2.84 %)
CABALETTA BIO INC
CABALETTA BIO INC
$2.19
$0.03 (1.62 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$0.64
$-0.05 (-7.40 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00